Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.

Journal of psychopharmacology (Oxford, England) - 1 May 2024

Knuijver Thomas, Ter Heine Rob, Schellekens Arnt F A, Heydari Paniz, Lucas Luc, Westra Sjoerd, Belgers Maarten, van Oosteren Toon, Verkes Robbert Jan, Kramers Cornelis

Abstract excerpt

OBJECTIVE: Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. METHODS: The study was performed in 14...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Long QT Syndrome

Share to Opioid-Related Disorders

Share to Substance Withdrawal Syndrome

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 38519421
DOI: 10.1177/02698811241237873
PMCID: PMC11102648

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.PMID 38519421Read ↗

Systematic Evaluation of Adverse Drug Reactions Associated with Benzodiazepine Utilization: A Comprehensive ReviewSemantic proximity Read ↗

Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam.Semantic proximity Read ↗

Trends in Tramadol: Pharmacology, Metabolism, and Misuse.Semantic proximity Read ↗

A Multiscale Structural, Pharmacokinetic–Pharmacodynamic and Systems Pharmacology Framework Exploring a Plausible Interaction Between Cenobamate and Low-Dose Clobazam in Drug-Resistant EpilepsySemantic proximity Read ↗

CYP2D6 genotype and associated 5-HT3 receptor antagonist outcomes: A systematic review and meta-analysis.Semantic proximity Read ↗

Clinical and molecular pharmacology of etomidate.Semantic proximity Read ↗

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications.Semantic proximity Read ↗

Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.Semantic proximity Read ↗

Correlation of 1846G>A Polymorphism of CYP2D6 Gene with Haloperidol Efficacy and Safety in Patients with Alcoholic Hallucinoses.Semantic proximity Read ↗

Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.Semantic proximity Read ↗

Population Pharmacokinetics of Brexpiprazole in Japanese Healthy Subjects and Patients with SchizophreniaSemantic proximity Read ↗

Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.